StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Equities researchers at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Thursday. The firm set a “sell” rating on the stock.

Oragenics Trading Up 1.7 %

Oragenics stock opened at $0.26 on Thursday. The stock has a market cap of $3.18 million, a PE ratio of -0.04 and a beta of 0.85. The stock has a 50-day moving average price of $0.29 and a 200 day moving average price of $0.35. Oragenics has a 52 week low of $0.24 and a 52 week high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.